Metabolomic analysis for diagnosis of oral squamous cell carcinoma using machine learning

Oral squamous cell carcinoma (OSCC) undergoes significant metabolic reprogramming. Adopting metabolomics to identify altered metabolic enzymes and metabolites holds promise for the early and precise diagnosis of OSCC. However, most current workflows rely on single-perspective modeling and lack task-aware prioritization. They underextract metabolomic signals, limit classification robustness, and impede a traceable transition from untargeted discovery to targeted panels. Therefore, we propose Metabolomics-based Integrated Information Learning (MIIL), an interpretable framework for OSCC diagnosis and premalignant screening. MIIL prioritizes task-relevant metabolites to derive a compact biomarker panel for targeted assay development, while strengthening classification via decision-level fusion of heterogeneous learners. Initially, we collect 120 oral mucosa tissues from 40 OSCC patients, including 40 Cancer (CA) samples, 40 Margin-1 specimens (M1), and 40 Margin-2 tissues (M2). Moreover, MIIL conducts untargeted metabolomics analysis to identify the most significant differential metabolites contributing to OSCC diagnosis. Subsequently, targeted metabolomics techniques are exploited for in-depth analysis of amino acid metabolites. Finally, integrated learning models are combined via decision-level fusion of linear, probabilistic, and margin-based signals, supporting accurate OSCC classification. The final results demonstrate that this method excels in the CA.vs.M1, CA.vs.M2, and M1.vs.M2 diagnostic tasks, achieving mean accuracies of 88.33%, 91.67%, and 85.00%, respectively. Trial registration: Chinese Clinical Trial Registry (ChiCTR), ChiCTR2200064861; registered on 2023-04-23.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-04-24
DOI
https://doi.org/10.1007/s12672-026-04988-0
Primary Topic
Metabolomics and Mass Spectrometry Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metabolomic analysis for diagnosis of oral squamous cell carcinoma using machine learning

S L Li, Xiangjie Meng, Shang Han, Wei Yuan et al.
Discover Oncology
Metabolomics and Mass Spectrometry Studies
article

Metabolomic analysis for diagnosis of oral squamous cell carcinoma using machine learning

S L Li, Xiangjie Meng, Shang Han, Wei Yuan, Jiayi Rao, Lizheng Qin, Xin Huang
article en

Abstract

Oral squamous cell carcinoma (OSCC) undergoes significant metabolic reprogramming. Adopting metabolomics to identify altered metabolic enzymes and metabolites holds promise for the early and precise diagnosis of OSCC. However, most current workflows rely on single-perspective modeling and lack task-aware prioritization. They underextract metabolomic signals, limit classification robustness, and impede a traceable transition from untargeted discovery to targeted panels. Therefore, we propose Metabolomics-based Integrated Information Learning (MIIL), an interpretable framework for OSCC diagnosis and premalignant screening. MIIL prioritizes task-relevant metabolites to derive a compact biomarker panel for targeted assay development, while strengthening classification via decision-level fusion of heterogeneous learners. Initially, we collect 120 oral mucosa tissues from 40 OSCC patients, including 40 Cancer (CA) samples, 40 Margin-1 specimens (M1), and 40 Margin-2 tissues (M2). Moreover, MIIL conducts untargeted metabolomics analysis to identify the most significant differential metabolites contributing to OSCC diagnosis. Subsequently, targeted metabolomics techniques are exploited for in-depth analysis of amino acid metabolites. Finally, integrated learning models are combined via decision-level fusion of linear, probabilistic, and margin-based signals, supporting accurate OSCC classification. The final results demonstrate that this method excels in the CA.vs.M1, CA.vs.M2, and M1.vs.M2 diagnostic tasks, achieving mean accuracies of 88.33%, 91.67%, and 85.00%, respectively. Trial registration: Chinese Clinical Trial Registry (ChiCTR), ChiCTR2200064861; registered on 2023-04-23.

Discover Oncology
Capital Medical University (CN), Harbin Institute of Technology (CN), Beijing Obstetrics and Gynecology Hospital (CN)
Beijing Nova Program
Peace, Justice and strong institutions
Openalex Percentile: Top 13%
Metabolomics and Mass Spectrometry Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.